---
title: "Arrowhead Pharmaceuticals soars 20% as plozasiran hits Phase 3 endpoints"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293482101.md"
description: "Arrowhead (ARWR) jumps 20% after plozasiran meets primary endpoints in Phase 3 trials, cutting triglycerides by up to 81%."
datetime: "2026-07-22T13:40:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293482101.md)
  - [en](https://longbridge.com/en/news/293482101.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293482101.md)
generator: "portal-rs"
---

# Arrowhead Pharmaceuticals soars 20% as plozasiran hits Phase 3 endpoints

箭头制药 (ARWR.US) 盘中涨近 20%，现报 89.33 美元。

公司旗下药物 plozasiran 在严重高甘油三酯血症的Ⅲ期 SHASTA-3 和 SHASTA-4 试验中达到主要终点，甘油三酯中位数降幅分别达**79%**和**81%**，显著优于安慰剂组的**27%**。汇总数据显示急性胰腺炎事件显著减少，高危亚组降幅达**100%**。公司计划于 2026 年底向美国 FDA 提交补充新药申请，完整数据将于 8 月 30 日在欧洲心脏病学大会公布。

### Related Stocks

- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)

## Related News & Research

- [Can Arrowhead Pharmaceuticals (ARWR) Still Look Like A Bargain Following Its Phase 3 SHASTA Data?](https://longbridge.com/en/news/298165580.md)
- [Arrowhead Pharmaceuticals (ARWR) Stock Looks Cheap On Cash Flow Yet Fair On Sales](https://longbridge.com/en/news/298117407.md)
- [Public Employees Retirement System of Ohio Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR](https://longbridge.com/en/news/298105697.md)
- [Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/297869579.md)
- [Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials](https://longbridge.com/en/news/297536982.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**